<DOC>
	<DOC>NCT02906579</DOC>
	<brief_summary>To evaluate the impact of escalating doses of IW-1973 on endothelial function [using EndoPAT to measure fingertip small vessel pulse volume], blood pressure (BP), and heart rate.</brief_summary>
	<brief_title>A Phase 2 Trial of IW-1973, A Stimulator of Soluble Guanylate Cyclase (sGC), in Patients With Stable Type 2 Diabetes and Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<criteria>Patient is ambulatory male or female Patient's body mass index score is &gt;20 and &lt;40 kg/m2 at the Screening Visit Women of childbearing potential must have a negative pregnancy test at the time of checkin and must agree to use doublebarrier contraception throughout the duration of the study Patient's health is stable with no clinically significant findings on a physical examination Patient has type 2 (ie adult onset) diabetes mellitus diagnosed by a physician or nurse practitioner &gt; 6 months before the Screening Visit, and an entry HbA1c that does not mandate prompt intervention for improved control Patient has hypertension diagnosed by a physician or nurse pratictioner &gt; 6 months before the Screening Visit and BP within the protocol's acceptable range Patients must be on a stable regimen for glycemic control, and a stable regimen for hypertension control that includes an angiotensin converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB) Patient has abnormal endothelial function measured by the EndoPAT Other inclusion criteria per protocol Patient has a clinically significant active or unstable medical condition that, in the opinion of the Investigator, would preclude trial participation Patient is on medication(s) that when coadministered with a soluble guanylate cyclase (sGC) stimulator, could increase the risk of hypotension Patient has evidence of severe or active endorgan damage attributable to diabetes Patient has severe renal insufficiency, has undergone renal transplantation, or has planned renal transplantation Other exclusion criteria per protocol</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>